A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2012
At a glance
- Drugs Veltuzumab (Primary)
- Indications B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Immunomedics
- 18 May 2009 Results have been published online in the Journal of Clinical Oncology; announed by Immunomedics in a media release.
- 21 Jan 2008 Status changed from in progresss to completed.
- 18 Jan 2007 Status change